Professor Osama Badary
Vice Dean Postgraduate Studies and Research, Head of clinical Pharmacy Practice Department and Supervisor of The Environmental and Community Services
305 Building K

• Vice Dean Pharmaceutical Research Faculty of Pharmacy, The British University in Egypt BUE Cairo Egypt. Sept 2019-current
• Chairman National Organization for Drug Control and Research (NODCAR), Cairo, Egypt Sept 2013- Sept 2019

• Head, Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Egypt Aug 2006- Aug 2013
• Vice Dean, Faculty of Pharmacy, Helwan University, Cairo, Egypt Feb 2003- July 2006
• Head, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Helwan University, Helwan, Cairo, Egypt Jan 2002- Jan 2003
• Professor, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Egypt. (Dec 2001-Jan 2002).
• Assistant Professor, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Egypt. (1998-2001).
• Assistant Professor, Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Saud University, Riyadh, Saudi Arabia (1996-1998)
• Lecturer, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. (1991-1996)
• Assistant Researcher, Faculty Of Pharmacy , University of Georgia, USA .1990
• Assistant Lecturer, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. (1988-1991)
• Demonstrator, Department of Pharmacology and Toxicology Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. (1985-1988).

Education
  • Ph.D. Pharmaceutical Sciences (Pharmacology and Toxicology), Faculty of Pharmacy, Al-Azhar University, Egypt and University of Georgia (UGA), GA, USA (1991).
  • M.Sc. Pharmaceutical Sciences (Pharmacology and Toxicology), Faculty of Pharmacy, Al-Azhar University, Egypt (1988).
  • Diploma Biochemical Analysis, Faculty of Pharmacy, Al-Azhar University, Egypt (1986).
  • Pharmaceutical Sciences, Faculty of Pharmacy, Cairo University, Egypt (1983)
Journal Articles

 

 

 

2020

The Novel SOD Mimetic GC4419 Increases Cancer Cell Killing With Sensitization to Ionizing Radiation While Protecting Normal Cells

1

El-Mahdy MA, Alzarie YA, Hemann C, Badary OA, Nofal S, Zweier JL.

 

Free Radic Biol Med. 2020;S0891-5849(20)31179-5.

 

 

Vitamin D3 Ameliorates DNA Damage Caused by Developmental Exposure to Endocrine Disruptors in the Uterine Myometrial Stem Cells of Eker Rats.

2

 

Elkafas H, Ali M, Elmorsy E, et al.

 

 

Cells. 2020;9(6):1459. Published 2020 Jun 12.

 

 

Protective effects of morin against depressive-like behavior prompted by chronic unpredictable mild stress in rats: Possible role of inflammasome-related pathways

3

 

Hassan MM, Gad AM, Menze ET, Badary OA, El-Naga RN.

 

 

Biochem Pharmacol. 2020;180:114140.

 

 

Cross-Sectional Study on Awareness and Knowledge of COVID-19 Among Senior pharmacy Students

4

 

Hamza MS, Badary OA, Elmazar MM.

 

 

J Community Health. 2020;1-8.

 

2019

Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies.

5

Solayman MH, Langaee TY, Gong Y, Shahin MH, Turner ST, Chapman AB, Gums JG, Boerwinkle E, Beitelshees AL, El-Hamamsy M, El-Wakeel L, Cooper-DeHoff RM, Badary OA, Johnson JA.

 

Eur J Pharm Sci. 2019 Apr 1;131:93-98

 

2018

Thymoquinone alleviates the experimentally induced Alzheimer's disease inflammation by modulation of TLRs signaling.

6

Abulfadl YS, El-Maraghy NN, Ahmed AE, Nofal S, Abdel-Mottaleb Y, Badary OA.

 

Hum Exp Toxicol. 2018 Oct;37(10):1092-1104.

 

2018

Protective effects of thymoquinone on D-galactose and aluminum chloride induced neurotoxicity in rats: biochemical, histological and behavioral changes.

7

Abulfadl YS, El-Maraghy NN, Ahmed AAE, Nofal S, Badary OA.

 

Neurol Res. 2018 Apr;40(4):324-333

 

2017

EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.

8

El-Madani M, Colomban O, Tod M, Maillet D, Peron J, Rodriguez-Lafrasse C, Badary OA, Valette PJ, Lefort T, Cassier P, El-Shenawy SM, El-Demerdash E, Hommel-Fontaine J, Guitton J, Gagnieu MC, Ibrahim BM, Barrois C, Freyer G, You B.

 

Future Oncol. 2017 Apr;13(8):679-693.

 

2017

ASSOCIATION OF ADRB1 GENE DNA METHYLATION WITH ANTIHYPERTENSIVE RESPONSE TO METOPROLOL IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES 2 (PEAR-2) STUDY.

9

MH Solayman, TY Langaee, Y Gong, ST Turner, AB Chapman, JG Gums, ...‏

 

CLINICAL PHARMACOLOGY & THERAPEUTICS 101 (S 1), S47-S47‏

 

2016

THE EFFECT OF UGT1A6 POLYMORPHISM AT TWO LOCI ON THE CLINICAL RESPONSE TO VALPROIC ACID IN EPILEPTIC CHILDREN

10

EA Algharably, M El Hamamsy, SM Hassanein, NA Mohamed, ...‏

 

International Journal of Pharmaceutical Sciences and Research 7 (10), 3986‏

 

2016

A CLINICAL STUDY EVALUATING THE EFFECT OF IVABRADINE ON INFLAMMATION IN PATIENTS WITH NON ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES

11

M Adel, S Mansour, NA Sabri, OA Badary, MA Saleh‏

 

International Journal of Pharmaceutical Sciences and Research 7 (4), 1441‏

 

2016

Identification of suitable endogenous normalizers for qRT-PCR analysis of plasma microRNA expression in essential hypertension

12

MHM Solayman, T Langaee, A Patel, L El-Wakeel, M El-Hamamsy, ...‏

 

Molecular biotechnology 58 (3), 179-187‏

 

2016

A Prospective Pharmacokinetic Study of Docetaxel in Breast Cancer Patients in Relation to CYP3A4 Activity

13

M Omran, O Badary, A Helal, H Hafez, M Moneer, S Shouman‏

 

Clin Pharmacol Biopharm 5, 156‏

 

2016

Clinical Pharmacology & Biopharmaceutics

14

M Omran, O Badary, A Helal, S Shouman‏

 

2015

THE CLINICAL EFFECTS OF NITAZOXANIDE IN HEPATIC ENCEPHALOPATHY PATIENTS: A PILOT STUDY

15

AA Elrakaybi, ATA ElMoez, OA Badary‏

 

International Journal of Pharmaceutical Sciences and Research 6 (11), 4657‏

 

2015

Association of Plasma Microrna with Anti-hypertensive Response to Beta Blockers

16

MH Solayman, T Langaee, Y Gong, M El-hamamsy, L El-wakeel, ...‏

 

Clinical Pharmacology in Drug Development 4, 1-60‏

 

2015

Chemopreventive and therapeutic potentials of thymoquinone in HepG2 cells: mechanistic perspectives

17

A ElKhoely, HF Hafez, AM Ashmawy, O Badary, A Abdelaziz, A Mostafa, ...‏

 

Journal of natural medicines 69 (3), 313-323‏

 

2015

Metformin addition to chemotherapy in stage IV non-small cell lung cancer: an open label randomized controlled study

18

R Sayed, AS Saad, L El Wakeel, E Elkholy, O Badary‏

 

Asian Pac J Cancer Prev 16 (15), 6621-6‏

 

2015

Improvement in clinical outcomes of type 2 diabetic patients after pharmacist-physician collaborative care for dyslipidemia

19

S Ramzy, MA MerhanSamy, O Badary‏

 

International Journal 3 (3), 211-215‏

 

 

Folic Acid and Vitamin B Complex Improves Quality of Life in Hepatitis C Infected Patients Treated with Peginterferon and Ribavirin

20

2015

N Ashoush, M El-Hamamsy, M Schaalan, O Ahmed, M Elmazar, O Badary‏

Br J Med Health Res. 2(2)

 

 

 

2014

A clinical trial of propolis supplementation on type Ii diabetic patients treated with gliclazide and metformin.

21

N Hashem, A Elshamy, M Maher, OA Badary‏

 

Pharmacotherapy: The Journal Of Human Pharmacology And Drug Therapy 34 (10 …‏

 

2014

Implementation of clinical pharmacy services in a pediatric dialysis unit

22

R El Borolossy, L El Wakeel, I El Hakim, O Badary‏

 

Pediatric Nephrology 29 (7), 1259-1264‏

 

2014

Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism

23

NS Bazan, NA Sabry, A Rizk, S Mokhtar, OA Badary‏

 

Irish journal of medical science 183 (2), 161-172‏

 

2014

An open-label randomized controlled phase II study of clarithromycin (CL) plus CVP in patients (pts) with previously untreated stage III/IV indolent non Hodgkin lymphoma (NHL).

24

AS Saad, SM Shaheen, MH Elhamamsy, OA Badary‏

 

Journal of Clinical Oncology 32 (15_suppl), e19510-e19510‏

 

2013

Effect of Thymoquinone on Hepatic Fibrosis Induced in BALB/C Mice: Is It Always Beneficial?

25

NS Imama, R Kamel, OA Badary, AM Mostafa‏

 

Egyptian Journal of Basic and Clinical Pharmacology 3 (2), 11-20‏

 

2013

An Open-label Phase I Pilot Study of Continuous Intrapleural Infusion of Escalated Doses of Methotrexate in Malignant Pleural Mesothelioma

26

MMA Ellithy, NSEDM El, LM El Wakeel, KA Abdeltawab, OA Badary‏

 

American journal of clinical oncology 36 (5), 514-518‏

 

2013

The clinical outcome of adjuvant therapy with black seed oil on intractable paediatric seizures: a pilot study

27

M Shawki, L El Wakeel, R Shatla, ELS Gamila, S Ibrahim, O Badary‏

 

Epileptic disorders 15 (3), 295-301‏

 

2013

Effect of L-carnitine on behavioral disorder in autistic children

28

SF Fahmy, M El-Hamamsy, O Zaki, OA Badary‏

 

Value in Health 16 (3), A15‏

 

2013

The clinical outcome of adjuvant therapy with black seed oil on intractable pediatric seizures: a pilot study.

28

LM El Wakeel, R Shatla, M Shawki, S El Saeed, S Ismail, OA Badary‏

 

Pharmacotherapy: The Journal Of Human Pharmacology And Drug Therapy 33 (5), e58‏

 

2013

l-Carnitine supplementation improves the behavioral symptoms in autistic children

30

SF Fahmy, MH El-hamamsy, OK Zaki, OA Badary‏

 

Research in Autism Spectrum Disorders 7 (1), 159-166‏

 

2013

Paracetamol supplementation does not alter the antitumor activity and lung toxicity of bleomycin

31

GM Suddek, HA Salem, OA Badary, NM Gameil, HA El-Kashef‏

 

Journal of Food and Pharmaceutical Sciences 2 (1)‏

 

2013

Study of the effect of Allium porrum on osteoporosis induced in rats

32

SMA El-Shenawy, NAZ Yassin, OA Badary, MA EL-Moneem, ...‏

 

Der Pharmacia Lettre 5 (1), 188-198‏

 

2013

Study of the effect of Allium porrum on hypertension induced in rats

33

OA Badary, NAZ Yassin, S El-Shenawy, MA EL-Moneem, HM AL-Shafeiy‏

 

Revista latinoamericana de química 41 (3), 149-160‏

 

2012

Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients

34

NS Bazan, NA Sabry, A Rizk, S Mokhtar, O Badary‏

 

International journal of clinical pharmacy 34 (6), 837-844‏

 

2012

Ameliorative effects of resveratrol on liver injury in streptozotocin‐induced diabetic rats

35

N Hamadi, A Mansour, MH Hassan, F Khalifi‐Touhami, O Badary‏

 

Journal of biochemical and molecular toxicology 26 (10), 384-392‏

 

2012

PIH4 Is Sildenafil–Apomorphine Sublingual Combination Significantly More Effective than Sublingual Sildenafil in Treating Erectile Dysfunction?

36

MH Solayman, OA Badary, KA Salem, M El-Hamamsy‏

 

Value in Health 15 (4), A192‏

 

2012

An open label phase I pilot study of continuous intrapleural infusion of escalated doses of methotrexate in malignant pleural mesothelioma

37

LM El Wakeel, MA Ellithy, NSED El Baghdady, OA Badary, ...‏

 

PHARMACOTHERAPY 32 (5), E111-E112‏

 

2011

Reducing prescribing errors in the paediatric intensive care unit: an experience from Egypt

38

HZ Alagha, OA Badary, HM Ibrahim, NA Sabri‏

 

Acta Paediatrica 100 (10)‏

 

2011

1082 POSTER Nigella Sativa Oil Ameliorates Methotrexate-induced Liver Toxicity

39

R Labib, H Hafez, O Badary‏

 

European Journal of Cancer 47, S119‏

 

2010

Transcriptional and posttranscriptional regulation of CYP1A1 by vanadium in human hepatoma HepG2 cells

40

G Abdelhamid, A Anwar-Mohamed, OA Badary, AA Moustafa, ...‏

 

Cell biology and toxicology 26 (5), 421-434‏

 

2009

Hepatoprotective and antioxidant activity of phytic acid and/or catechin against carbon tetrachloride-induced hepatotoxicity in rats

41

S Hassan, MZ Rizk, F El-Sharkawi, O Badary, MO Kadry‏

 

Toxicology Letters 189, S265-S266‏

 

2009

1071 Nigella sativa L. oil ameliorates methotrexate-induced intestinal toxicity through antioxidant activity

42

R Labib, O Badary, H Hafez‏

 

European Journal of Cancer Supplements 7 (2), 106‏

 

2009

Acetyl‐l‐Carnitine Ameliorates Caerulein‐induced Acute Pancreatitis in Rats

43

HMM Arafa, RAM Hemeida, MIA Hassan, MH Abdel‐Wahab, OA Badary, ...‏

 

Basic & clinical pharmacology & toxicology 105 (1), 30-36‏

 

2009

Mechanical Strain in VSM Cells Triggers Vascular Remodeling and Hypertension and Activates Integrins in Profilin1 Transgenic Model

44

MDH Hassona, MM Awad, MA Alhaj, OA Badary, FM Hamada, ...‏

 

The FASEB journal 23 (1 Supplement), 704.6-704.6‏

 

2009

Glycemic control and therapeutic effect of Nigella sativa and Curcuma longa on rats with streptozotocin-induced diabetic hepatopathy.

45

AM Mohamed, FZ El-Sharkawy, SAA Ahmed, WM Aziz, OA Badary‏

 

Journal of Pharmacology and Toxicology 4 (2), 45-57‏

 

2008

The chemotherapeutic agents nocodazole and amsacrine cause meiotic delay and non-disjunction in spermatocytes of mice

46

SM Attia, OA Badary, FM Hamada, MH de Angelis, ID Adler‏

 

Mutation Research/Genetic Toxicology and Environmental Mutagenesis 651 (1 …‏

 

2007

Anti-fibrotic effect of meloxicam in a murine lung fibrosis model

47

HMM Arafa, MH Abdel-Wahab, MF El-Shafeey, OA Badary, FMA Hamada‏

 

European journal of pharmacology 564 (1), 181-189‏

 

2007

Anticlastogenic activity of thymoquinone against benzo(a)pyrene in mice

48

OA Badary, MF Abd-Ellah, MA El-Mahdy, SA Salama, FM Hamada‏

 

Food and chemical toxicology 45 (1), 88-92‏

 

2007

The possible synergestic role of phytic acid and catechin in ameliorating the deteriorative biochemical effects induced by carbon tetrachloride in rats

49

SA Hassan, MZ Rizk, F El-Sharkawi, O Badary, MO Kadry‏

 

J Appl Sci Res 3, 1449-1459‏

 

2007

Effect of Molokhia soup on blood sugar, hepatic antioxidant status & plasma lipid profile in diabetic rats

50

S Mahgoub, F El-Sharkawi, O Badary‏

 

The Egyptian journal of biochemistry & molecular biology, 305-325‏

 

2006

In vitro and in vivo effects of ferulic acid on gastrointestinal motility: inhibition of cisplatin-induced delay in gastric emptying in rats

51

OA Badary, AS Awad, MA Sherief, FMA Hamada‏

 

World Journal of Gastroenterology: WJG 12 (33), 5363‏

 

2006

Antioxidant flavonol glycosides from Schinus molle

52

MS Marzouk, FA Moharram, EG Haggag, MT Ibrahim, OA Badary‏

 

Phytotherapy Research 20 (3), 200-205‏

 

2005

Orthovanadate increased the frequency of aneuploid mouse sperm without micronucleus induction in mouse bone marrow erythrocytes at the same dose level

53

SM Attia, OA Badary, FM Hamada, MH de Angelis, ID Adler‏

 

Mutation Research/Genetic Toxicology and Environmental Mutagenesis 583 (2 …‏

 

2005

Serotonin glucuronidation by Ah receptor-and oxidative stress-inducible human UDP-glucuronosyltransferase (UGT) 1A6 in Caco-2 cells

54

C Köhle, OA Badary, K Nill, BS Bock-Hennig, KW Bock‏

 

Biochemical pharmacology 69 (9), 1397-1402‏

 

2005

Naringenin attenuates cisplatin nephrotoxicity in rats

55

OA Badary, S Abdel-Maksoud, WA Ahmed, GH Owieda‏

 

Life sciences 76 (18), 2125-2135‏

 

2004

Cardiac DT‐diaphorase contributes to the detoxification system against doxorubicin‐induced positive inotropic effects in guinea‐pig isolated atria

56

OA Badary, AS Awad, S Abdel‐Maksoud, F Hamada‏

 

Clinical and experimental pharmacology and physiology 31 (12), 856-861‏

 

2004

Metabolism and transport of serotonin, a selective substrate of human oxidative/electrophile stress-inducible UDP-glucuronosyl-transferase UGT1A6, in Caco-2 cell monolayers

57

C Kohle, OA Badary, K Nill, B Bock-Hennig, KW Bock‏

 

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 369, R108-R108‏

 

2003

Goitrogenic activity of p‐coumaric acid in rats

58

F Khelifi‐Touhami, RA Taha, OA Badary, A Lezzar, F Hamada‏

 

Journal of biochemical and molecular toxicology 17 (6), 324-328‏

 

2003

A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2

59

AM Mansour, J Drevs, N Esser, FM Hamada, OA Badary, C Unger, ...‏

 

Cancer research 63 (14), 4062-4066‏

 

2003

Frequent co-occurrence of the TATA box mutation associated with Gilbert’s syndrome (UGT1A1* 28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6* 2 …

60

C Köhle, B Möhrle, PA Münzel, M Schwab, D Wernet, OA Badary, ...‏

 

Biochemical pharmacology 65 (9), 1521-1527‏

 

2003

Effects of benzo [a] pyrene on tissue activities of metabolizing enzymes and antioxidant system in normal and protein‐malnourished rats

61

OA Badary, HM AbdEl‐Gawad, RA Taha, AA Ali, F Hamada‏

 

Journal of biochemical and molecular toxicology 17 (2), 86-91‏

 

2003

Thymoquinone is a potent superoxide anion scavenger

62

OA Badary, RA Taha, AM Gamal El-Din, MH Abdel-Wahab‏

 

Drug and chemical toxicology 26 (2), 87-98‏

 

2003

Etoposide and merbarone are clastogenic and aneugenic in the mouse bone marrow micronucleus test complemented by fluorescence in situ hybridization with the mouse minor …

63

SM Attia, U Kliesch, G Schriever‐Schwemmer, OA Badary, FM Hamada, ...‏

 

Environmental and molecular mutagenesis 41 (2), 99-103‏

 

2002

Molecular cytogenetic analysis in mouse sperm of chemically induced aneuploidy: studies with topoisomerase II inhibitors

64

SM Attia, TE Schmid, OA Badary, FM Hamada, ID Adler‏

 

Mutation Research/Genetic Toxicology and Environmental Mutagenesis 520 (1), 1-13‏

 

2002

Cumulative Author Index for MUTGEN 2002

65

FA Atienzar, P Venier, AN Jha, MH Depledge, SM Attia, TE Schmid, ...‏

 

Mutation Research 521, 213-226‏

 

2002

Polymorphic metabolizing genes and susceptibility to atherosclerosis among cigarette smokers

66

SA Salama, WW Au, GC Hunter, RG Sheahan, OA Badary, ...‏

 

Environmental and molecular mutagenesis 40 (3), 153-160‏

 

2001

Cytogenetic assays for monitoring populations exposed to environmental mutagens.

67

WW Au, OA Badary, MY Heo‏

 

Occupational medicine (Philadelphia, Pa.) 16 (2), 345-357‏

 

2001

Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis.

68

OA Badary, EDAM Gamal‏

 

Cancer detection and prevention 25 (4), 362-368‏

 

2000

The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats

69

OA Badary, AB Abdel-Naim, MH Abdel-Wahab, FMA Hamada‏

 

Toxicology 143 (3), 219-226‏

 

2000

Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL

70

OA Badary, AB Abdel-Naim, AE Khalifa, FMA Hamada‏

 

Naunyn-Schmiedeberg's archives of pharmacology 361 (3), 339-344‏

 

2000

Evaluation of cisplatin combined with ondansetron in Ehrlich ascites carcinoma in vitro and in vivo.

71

OA Badary, SM Sharaby, SA Kenawy, EE El-Denshary, FM Hamada‏

 

Tumori 86 (2), 153-156‏

 

2000

Antitumor activity of thymoquinone against fibrosarcoma tumorigenesis

72

OA Badary, AMG El-Din‏

 

Cancer Molecular Biology 7, 1515-1526‏

 

2000

Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats

73

OA AL-SHABANAH, HA EL-KASHEF, OA BADARY, AM AL-BEKAIRI, ...‏

 

Pharmacological research 41 (1), 31-37‏

 

1999

Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice

74

OA Badary‏

 

Journal of ethnopharmacology 67 (2), 135-142‏

 

1999

Inhibition of benzo (a) pyrene-induced forestomach carcinogenesis in mice by thymoquinone.

75

OA Badary, OA Al-Shabanah, MN Nagi, AC Al-Rikabi, MM Elmazar‏

 

European journal of cancer prevention: the official journal of the European …‏

 

1999

The protective action of thymol against carbon tetrachloride hepatotoxicity in mice

76

K Alam, MN Nagi, OA Badary, OA Al-Shabanah, AC Al-Rikabi, ...‏

 

Pharmacological research 40 (2), 159-163‏

 

1999

Effect of bromocriptine on uterine contractility in near-term pregnant rats

77

AM Moustafa, EM El-Sayed, OA Badary, AM Mansour, FMA Hamada‏

 

Pharmacological research 39 (2), 89-95‏

 

1999

Thymoquinone protects against carbon tetrachloride hetatotoxicity in mice via an antioxidant mechanism

78

MN Nagi, K Alam, OA Badary, OA Al‐Shabanah, HA Al‐Sawaf, ...‏

 

IUBMB Life 47 (1), 153-159‏

 

1999

L-Histidinol attenuates Fanconi syndrome induced by ifosfamide in rats

79

OA Badary‏

 

Nephron Experimental Nephrology 7 (4), 323-327‏

 

1998

Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice.

80

OA Badary, OA Al-Shabanah, NM Al-Gharably, MMA Elmazar‏

 

Anti-cancer drugs 9 (9), 809-815‏

 

1998

Effects of Ehrlich ascites carcinoma cells on the responses of non-pregnant and pregnant uterine smooth muscles of mice to oxytocin and acetylcholine.

81

HA El-Kashef, O Badary, MM El-Mazar, O Al-Shabana, A Al-Bekiri‏

 

Journal of experimental & clinical cancer research: CR 17 (3), 259-262‏

 

1998

EFFECTS OFl-HISTIDINOL ON THE ANTITUMOUR ACTIVITY AND ACUTE CARDIOTOXICITY OF DOXORUBICIN IN MICE

82

OA AL-SHABANAH, OA BADARY, NM AL-GHARABLY, HA AL-SAWAF‏

 

Pharmacological research 38 (3), 225-230‏

 

1998

Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity.

83

OA Al-Shabanah, OA Badary, MN Nagi, NM Al-Gharably, AC Al-Rikabi, ...‏

 

Journal of experimental & clinical cancer research: CR 17 (2), 193-198‏

 

1998

Acute and subchronic toxicity of thymoquinone in mice

84

OA Badary, OA Al‐Shabanah, MN Nagi, AM Al‐Bekairi, M Elmazar‏

 

Drug Development Research 44 (2‐3), 56-61‏

 

1998

Pharmacokinetics and acute cardiotoxicity of doxorubicin after intravenous administration to rats with streptozotocin-induced diabetes mellitus.

85

OA Al-Shabanah, OA Badary, HA El-Kashef, AM Al-Bekairi, MMA Elmazar‏

 

FASEB JOURNAL 12 (4), A410-A410‏

 

1998

Taurine attenuates Fanconi syndrome induced by ifosfamide without compromising its antitumor activity

86

OA Badary‏

 

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 10 …‏

 

1997

Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity

87

OA Badary, MN Nagi, OA Al-Shabanah, HA Al-Sawaf, MO Al-Sohaibani, ...‏

 

Canadian Journal of Physiology and Pharmacology 75 (12), 1356-1361‏

 

1997

Effect of L-histidinol on cisplatin nephrotoxicity in the rat

88

OA Badary, MN Nagi, HA Al-Sawaf, M Al-Harbi, AM Al-Bekairi‏

 

Nephron 77 (4), 435-439‏

 

1997

Protective Effect of Thymoquinone Against Carbon Tetra-Chloride-Induced Hepatotoxicity in Mice

89

NM Al-Gharably, OA Badary, MN Nagi, OA Al-Shabanah, HA Al-Sawaf, ...‏

 

Research Communications in Pharmacology and Toxicology 2, 41-50‏

 

1996

ALTERED UTERINE SENSITIVITY TO OXYTOCIN AND PROSTAGLANDIN F2αIN DIMETHYLBENZ (a) ANTHRACENE (DMBA)-INDUCED RAT MAMMARY CARCINOMA: THE EFFECTS OF TAMOXIFEN AND/OR RECOMBINANT …

90

OA BADARY, AM AGHA, ELSM EL-SAYED, FMA HAMADA‏

 

Pharmacological research 34 (3-4), 99-103‏

 

1996

Does tissue polypeptide-specific antigen (TPS) relate to tissue polypeptide antigen (TPA) in Ehrlich ascites carcinoma (EAC)-bearing mice?

91

AB Halim, O ElAhmady, S Eissa, OA Badary, A Agha, P Oehr‏

 

JOURNAL OF TUMOR MARKER ONCOLOGY 11 (3), 23-28‏

 

1996

Long-Term Preventive Regimen of Tamoxifen and Recombinant Human Interferon 2b on Dimethylbenz (a) anthracene

92

AM Agha, OA Badary, A Gamal El-Din, Y Hafez, O El-Ahmady‏

 

CANCER MOLECULAR BIOLOGY 3, 761-772‏

 

1995

INTERFERON ENHANCEMENT OF TAMOXIFEN EFFICACY IN EHRLICH ASCITES-CARCINOMA-A FOLLOW-UP-STUDY OF TISSUE POLYPEPTIDE ANTIGEN

93

OA Badary, AM Agha, AB Halim, O ELAHMADY‏

 

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 14 (2), 225-232‏

 

1992

ADRENAL NECROSIS AND HIGH-FAT DIETS IN FEMALE SPRAGUE-DAWLEY RATS GIVEN 7, 12-DIMETHYLBENZ (A) ANTHRACENE (DMBA)

94

OR BUNCE, DK HARTLE, O BADARY, R BRODERSON‏

 

FASEB JOURNAL 6 (4), A1394-A1394‏

 

1991

EFFECT OF ACUTE COLD STRESS ON TYROSINE-HYDROXYLASE MESSENGER-RNA INDUCTION IN ADRENAL-MEDULLA OF SPONTANEOUSLY HYPERTENSIVE RATS (SHR)

95

OA BADARY, DK HARTLE‏

 

FASEB JOURNAL 5 (6), A1483-A1483‏

 

1991

POTENTIATION OF ANTITUMOR-ACTIVITY OF MITOMYCIN-C BY VERAPAMIL IN EHRLICH ASCITES-CARCINOMA

96

AM OSMAN, FMA HAMADA, AHA ELAZIZ, OA BADARY, SM HAMZA‏

 

FASEB JOURNAL 5 (5), A1261-A1261‏

 

1991

DECREASED ADRENAL-MEDULLARY TYROSINE-HYDROXYLASE MESSENGER-RNA IN DMBA (7, 12-DIMETHYLBENZ (A) ANTHRACENE)-INDUCED MAMMARY-CARCINOMA

97

OR BUNCE, OA BADARY, S ABOUELELA, DK HARTLE‏

 

FASEB JOURNAL 5 (5), A927-A927‏

 

1991

Decreased adrenal medullary tyrosine hydroxylase mRNA in DMBA (7, 12-dimethylbenz (a) anthracene)-induced mammary carcinoma

98

OR Bunce, OA Badary, S Abou El-Ela, DK Hartle‏

 

FASEB Journal (Federation of American Societies for Experimental Biology …‏

 

1991

RAPID INDUCTION OF TYROSINE-HYDROXYLASE MESSENGER-RNA IN RAT ADRENAL-MEDULLA DURING AREA POSTREMA ELECTRICAL-STIMULATION

99

DK HARTLE, OA BADARY, AS SOLIMAN‏

 

FASEB JOURNAL 5 (5), A1412-A1412‏

 

1991

INCREASED TYROSINE-HYDROXYLASE MESSENGER-RNA IN ADRENAL-MEDULLA AFTER META-CHLOROPHENYLPIPERAZINE TREATMENT IN CONSCIOUS RATS

100

J HILL, OA BADARY, AS SOLIMAN, DK HARTLE‏

 

FASEB JOURNAL 5 (5), A1214-A1214‏

 

1991

CINNARIZINE ENHANCEMENT OF METHOTREXATE ANTITUMOR EFFICACY IN EHRLICH ASCITES-CARCINOMA

101

FMA HAMADA, AM OSMAN, AHA ELAZIZ, OA BADARY, SM HAMZA‏

 

FASEB JOURNAL 5 (5), A1261-A1261‏

 
Conference Papers

1. The 6th African Medicines Regulators Conference AMRC AMA Strategy, Operating and Financing Model”2 – 4 OCTOBER 2019 VICTORIA FALLS, ZIMBABWE
2. The 4th Biennial Conference on Medical Product regulation in Africa (SCOMRA) VICTORIA FALLS, ZIMBABWE 30th September – 1st October 2019
3. 6 th Meeting OF Technical Working Group on Medicine Policy and Regulatory Reforms (TWG-MPRR) 2 OCTOBER 2019 VICTORIA FALLS, ZIMBABWE
4. International consultation meeting to discuss Good Regulatory Practices (GRP) for national medicines discuss a revised draft guideline on Good Regulatory Practices (GRP 21-22 September 2019 Geneva Switzerland
5. International consultation meeting to discuss comments received, draft policy, definition and operation guidance on WHO Listed Authorities (WLA 19 - 20 September 2019 Geneva Switzerland
6. Participant at official EXPO 2019 meeting "Mediterranean and African medical products markets. Morocco Feb 2019.
7. Participant at the 2nd AMQF meeting, Marrakesh, Morocco, Feb 2019.
8. Invited speaker in the 5th FUE international conference of pharmaceutical sciences "pharmaceutical industry affairs panel" Jan 2019.
9. Member in the 5th meeting of African Medicines Regulatory Harmonization (AMRH) Technical Working Group (TWG) Midrand, South Africa, Oct 2018.
10. Invited speaker at Egypt Pharma Regulatory Conference "Entering Middle East and African Markets", Cairo 2018.
11. Chair session at the 2nd international conference of the faculty of Pharmacy – Ain-Shams University "Future Trends For the Development of Pharmaceutical Education and Research" Cairo – Nov 2018
12. Speaker and Egypt representative at the World Health Organization conference entitled "Eastern Mediterranean Drug Regulatory Authorities Conference (EMDRAC)" Jordan, May 2017.
13. Egypt's representative at the 8th Annual Network of Official Medicines Control Laboratories- Middle East North Africa (NOMCoL-MENA), Morocco, Feb 2017.
14. Egypt's representative in the committee meeting for establishment of African Medicine Agency (AMA), Tunisia, July 2017.
15. Speaker at the "XXXIV International Scientific Conference of Pharmaceutical Sciences" Cairo, Dec 2017.
16. Egypt's representative at the fourth meeting of committee for establishment of African Medicine Agency (AMA), Ethiopia, Feb 2017.
17. Speaker and Egypt's representative at ‘3rd India-Africa Health Forum & 3rd Edition of Global Exhibition on services (GES), India, April 2017.
18. Session chair in the 4th FUE International Conference of Pharmaceutical Sciences (4th FUE-ICPS), Cairo, February 2017.
19. Egypt's representative at high level meeting in the Danish ministry of health, Denmark, May 2017.
20. Egypt's representativeat the advisory meeting for developing laws regarding trading and quality control of pharmaceuticals and medical devices in Africa, Ethiopia, 2016.
21. Egypt's representative at the second meeting of advisory committee for establishment of African Medicine Agency (AMA), Ethiopia, June 2016.
22. Egypt's representative at the scientific African conference for pharmaceutical quality control , Ethiopia, December 2015.
23. Second Technical Meeting on the Development and Harmonization of Standards on Pharmaceuticals and Vaccines among OIC Member States 25-26 November 2014, Malaysia.
24. Session chair, Speaker and Egypt's representative in "The First Conference for Medicines Regulatory Authorities in Sudan and Neighboring Countries" Khartoum, Sudan, December 2014.
25. Session chair in the "XXXII Conference of Pharmaceutical Sciences" Cairo, December 2011.
26. Member of the scientific committee of the Golden Jubilee conference of the Egyptian Society of Pharmacology & Experimental Therapeutics (ESPET), Cairo, May 2007.
27. Egyptian Society of Pharmacology & Experimental Therapeutics (ESPET) conference, Cairo, May 2007.
28. Speaker at the "3rd Annual Congress on Towards Patient Education, Patient Rights" Cairo, December 2006.
29. Speaker at the 8th International Conference on Environmental Mutagens. Shizuoka, Japan, Oct 21-26, 2001.
30. Speaker at "Al-Azhar second international conference of recent advances in pharmaceutical technology and biological sciences" Cairo, December 2001.
31. Giving a lecture entitled "Chemopreventive potential of Thymoquinone" at Tubingen University, Germany, July 2001.
32. Poster presentation at Federal American Association Experimental Biology (FASEB) conference, USA 1998.
33. Speaker at "Al-Azhar first international conference of recent advances in pharmaceutical technology and biological sciences" Cairo, December 1995.
34. Poster presentation at Federal American Association Experimental Biology (FASEB) conference, USA 1992.
35. Three poster presentation at Federal American Association Experimental Biology (FASEB) conference, USA 1991.

Awards

1. Recipient of the Gold Medal and National Appreciation Award. The National Scientific Day February 2020.
2. Recipient of The State Merit Award in Medical Sciences, 2017.
3. Recipient of The Shoman Prize in Medical Sciences (1999), Amman, Jordan for the research originality and the outstanding contribution in the field of Medical Sciences in the Arab World.
4. Fulbright Appreciation Certificate (2007-2009)
5. Alexander von Humboldt Grant (2001-2006): by The Alexander von Humboldt Foundation. Faculty of Medicine, Tuebingen University, Tuebingen, Germany.
6. UICC Yamagiwa-Yoshida Memorial International Cancer Grant (2000) funded by the Kyowa Hakko Kogya Ltd., Toray Industries Inc., Tokyo, and the Japan National Committee for Union International Contra Cancer (UICC). Toxicology Division, Department of Preventive Medicine and Community Health, (UTMB), Galveston, Texas, USA.
7. Vice President of Arab Academy for Development of Pharmaceutical Skills (ADPS).
8. President of the Scientific Board of the National Egyptian Clinical Pharmacy Fellowship.
9. Certificates of appreciation from the Egyptian National Committee for Biochemistry & Molecular Biology (NCBMB) 2014-2015
10. Certificate of appreciation from National Research Centre (NRC) 2016.
11. Certificate of appreciation from Central Administration for Pharmaceutical Affairs (CAPA) February 2017.